Fangfang Liu

State Key Laboratory Of Metabolic Dysregulation & Prevention And Treatment Of Esophageal Cancer
Zhengzhou, 450000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Targeting SRSF6 to Enhance Cisplatin Sensitivity by Modulating Redox Balance via NFE2L1 exon 4 Splicing in ESCC.

Targeting SRSF6 to Enhance Cisplatin Sensitivity by Modulating Redox Balance via NFE2L1 exon 4 Splicing in ESCC.

Journal: International journal of biological sciences

Published: January 16, 2026

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway.

Journal: Materials today. Bio

Published: March 20, 2025

Inflammation in cancer: therapeutic opportunities from new insights.

Inflammation in cancer: therapeutic opportunities from new insights.

Journal: Molecular cancer

Published: October 10, 2024

Elongation factor 2 in cancer: a promising therapeutic target in protein translation.

Elongation factor 2 in cancer: a promising therapeutic target in protein translation.

Journal: Cellular & molecular biology letters

Published: August 12, 2024

Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2.

Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2.

Journal: Science China. Life sciences

Published: June 17, 2024

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.

Journal: Molecular cancer

Published: April 17, 2024

NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway.

NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway.

Journal: Cellular and molecular life sciences : CMLS

Published: February 23, 2023

Integrins in cancer: Emerging mechanisms and therapeutic opportunities.

Integrins in cancer: Emerging mechanisms and therapeutic opportunities.

Journal: Pharmacology & therapeutics

Published: February 07, 2023

3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo.

3,3'-Diindolylmethane plus Eflornithine suppress DNA Replication and Cell Cycle in Esophageal Squamous Cell Carcinoma in vivo.

Journal: Journal of Cancer

Published: July 29, 2021

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.

Journal: Oncogene

Published: April 08, 2021

Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma.

Targeting integrin αvβ3 with indomethacin inhibits patient-derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma.

Journal: Clinical and translational medicine

Published: January 26, 2021

Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.

Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 29, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026